To put a bit more commentary to this interview here are the key...

To put a bit more commentary to this interview here are the key points I got out of it:

1. it takes a bloody long time to get a drug/ therapy to market…..nothing new here
2. raising money be it $1.00 or $1 million is difficult and spending it wisely is important
3. there are no short cuts to the regulatory process; it takes time; it takes money and you have do it right
4. trial design is extremely important and not all trials are comparable ; opthea phase II trial was one of the largest; it gave a lot of data and helped with design of phase III
5. data is everything
6. no point having a successful drug if you don’t have physicians who want to use it; you need to spend money on educating medicos and getting opinion leaders in place early
7. there is a lot of time where a company has nothing news worthy to report but there is lots happening behind the scenes
8. you have to have investors that understand and are are confident in what you are doing and are there for the the whole journey
9. The team and having the right people on board at the right time is very important. Megan pointed out that while she had never commercialised a drug she had people on her board as well as consultants who had.